Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Journal of Biomolecular Screening
|
September 11, 2013
A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity
Justin D Boyd, Peter Lee, Marisa S Feiler, et al.
Mbio
|
February 16, 2012
A new means to identify type 3 secreted effectors: functionally interchangeable class IB chaperones recognize a conserved sequence
Sonia C P Costa, Alexa M Schmitz, Fathima F Jahufar, et al.
Frontiers in Cellular Neuroscience
|
June 9, 2022
GW5074 Increases Microglial Phagocytic Activities: Potential Therapeutic Direction for Alzheimer's Disease
Sarah M Connor, Mamunur Rashid, Katie J Ryan, et al.
Neurobiology of Disease
|
December 17, 2017
Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons
Jason Schapansky, Saurabh Khasnavis, Mark P DeAndrade, et al.
Cell Reports
|
August 25, 2015
Genomic DISC1 Disruption in hiPSCs Alters Wnt Signaling and Neural Cell Fate
Priya Srikanth, Karam Han, Dana G Callahan, et al.
Plos One
|
March 3, 2010
Angiogenic factors stimulate growth of adult neural stem cells
Andreas Androutsellis-Theotokis, Maria A Rueger, Deric M Park, et al.
Journal of Lipid Research
|
January 12, 2024
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
Madeline M Vroom, Hanxin Lu, Maggie Lewis, et al.
Communications Medicine
|
April 29, 2025
Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
Justin D Boyd, Shixia Wang, Hsiao-Wen Lin, et al.
Science Translational Medicine
|
December 22, 2017
A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants
Katie J Ryan, Charles C White, Kruti Patel, et al.
Nature Medicine
|
June 20, 2024
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Journal of Biomolecular Screening
|
September 11, 2013
A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity
Justin D Boyd, Peter Lee, Marisa S Feiler, et al.
Mbio
|
February 16, 2012
A new means to identify type 3 secreted effectors: functionally interchangeable class IB chaperones recognize a conserved sequence
Sonia C P Costa, Alexa M Schmitz, Fathima F Jahufar, et al.
Frontiers in Cellular Neuroscience
|
June 9, 2022
GW5074 Increases Microglial Phagocytic Activities: Potential Therapeutic Direction for Alzheimer's Disease
Sarah M Connor, Mamunur Rashid, Katie J Ryan, et al.
Neurobiology of Disease
|
December 17, 2017
Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons
Jason Schapansky, Saurabh Khasnavis, Mark P DeAndrade, et al.
Cell Reports
|
August 25, 2015
Genomic DISC1 Disruption in hiPSCs Alters Wnt Signaling and Neural Cell Fate
Priya Srikanth, Karam Han, Dana G Callahan, et al.
Plos One
|
March 3, 2010
Angiogenic factors stimulate growth of adult neural stem cells
Andreas Androutsellis-Theotokis, Maria A Rueger, Deric M Park, et al.
Journal of Lipid Research
|
January 12, 2024
VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
Madeline M Vroom, Hanxin Lu, Maggie Lewis, et al.
Communications Medicine
|
April 29, 2025
Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide
Justin D Boyd, Shixia Wang, Hsiao-Wen Lin, et al.
Science Translational Medicine
|
December 22, 2017
A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants
Katie J Ryan, Charles C White, Kruti Patel, et al.
Nature Medicine
|
June 20, 2024
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Pepijn Eijsvogel, Pinaki Misra, Luis Concha-Marambio, et al.
Page
of 3